A probe from the UK’s competition watchdog has resulted in an £8 million (US$9.7 million) payment from Aspen Pharma to Britain’s National Health Service (NHS).
The South African drugmaker agreed to make the payment, as part of a wider package, after the Competition and Markets Authority uncovered “anti-competitive arrangements” regarding the supply of the life-saving medicine fludrocortisone.
The drug is primarily used to treat primary or secondary adrenal insufficiency, commonly known as Addison’s disease.
The payment to the NHS and the firm’s admission of illegality, as well as an additional fine of up to £2.1 million (US$2.5 million), will forestall any legal action from the UK government.
Full Content: Gov UK
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI